23-1322m Help Protect Infants with Nirsevimab at No Cost through VFC Program
Date: 11/16/23
Birthing and pediatric hospitals can save $495 per dose by enrolling in the program
Nirsevimab (Beyfortus™) will soon be available at no cost to facilities and sites enrolled in the California Vaccines for Children (VFC) Program.
Nirsevimab has shown to be highly effective in preventing hospitalization and admission for intensive care for RSV infection. RSV causes 80,000 hospitalizations and 300 deaths each year. Nirsevimab should be given to infants to protect them from returning to the hospital with severe RSV infections:
- Shortly after birth to all infants born between October and March, or
- Later during infancy to those born in the spring and summer.
Enroll in the VFC Program today
We encourage birthing and pediatric hospitals serving Medi-Cal members to enroll in the VFC Program to ensure newborns get immunized.
- Go to eziz website to learn more about enrolling.
- Providers can also call 877-243-8832 for enrollment support.
Additional information
Refer to any of the tools below for information about the VFC Program and Nirsevimab to help your efforts to protect infant health.
Description | Links |
|---|---|
VFC site enrollment | |
Nirsevimab guidance from the Centers for Disease Control and Prevention | |
RSV FAQs | |
RSV resource for providers and patients |
This information applies to Hospitals.